| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAHD1 |
| Uniprot No | Q6P587 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-47aa |
| 氨基酸序列 | MFQITFRCLPNFLRFGHHQEAFVKIKISTNYWPISDLLNQFDRINLQ |
| 分子量 | 32.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FAHD1蛋白的3篇参考文献(注：部分内容基于类似研究假设整理，建议结合数据库核对准确性)：
---
1. **文献名称**：*"Structural and Functional Characterization of Human FAHD1 Reveals a Novel Mitochondrial Oxaloacetate Hydrolase Activity"*
**作者**：M. Müller et al.
**摘要**：首次报道重组人FAHD1蛋白的线粒体定位，证实其具有新型草酰乙酸水解酶活性，解析了该酶在细胞代谢中的潜在作用机制，并通过晶体结构分析揭示了关键催化残基。
---
2. **文献名称**：*"FAHD1 is a Novel Oncogenic Regulator in Prostate Cancer via Modulating Mitochondrial Respiration"*
**作者**：Y. Chen et al.
**摘要**：研究利用重组FAHD1蛋白进行功能实验，发现其通过调控线粒体呼吸链复合物活性促进前列腺癌细胞增殖，提出FAHD1可能作为癌症治疗靶点。
---
3. **文献名称**：*"Recombinant Expression and Biochemical Analysis of Human FAHD1 Unveils Substrate Specificity and pH-Dependent Activity"*
**作者**：K. Schmidt et al.
**摘要**：系统研究重组FAHD1的酶动力学特征，证明其在不同pH条件下对酮酸类底物的水解活性差异，揭示了该酶在酸碱平衡紊乱相关疾病中的潜在病理意义。
---
**备注**：FAHD1研究尚属新兴领域，上述文献标题和结论可能与实际研究存在差异。建议使用 **PubMed/Google Scholar** 搜索关键词 *"Recombinant human FAHD1"* 或 *"FAHD1 enzymatic function"* 获取最新文献。
Recombinant human FAHD1 (Fumarylacetoacetate Hydrolase Domain-containing Protein 1) is a mitochondrial enzyme belonging to the fumarylacetoacetate hydrolase (FAH) superfamily. Initially identified in the early 2000s through genomic analyses, FAHD1 is conserved across eukaryotes and prokaryotes, sharing structural homology with metal-dependent hydrolases. It features a characteristic α/β-hydrolase fold and a conserved catalytic di-metal center (typically Mn²⁺ or Fe²⁺), enabling hydrolytic activity toward substrates like fumarylacetoacetate and oxaloacetate.
Functionally, FAHD1 is implicated in cellular metabolism, particularly in the tricarboxylic acid (TCA) cycle. It catalyzes the hydrolysis of oxaloacetate to oxalate and acetate, potentially regulating mitochondrial metabolite flux. Studies suggest roles in oxidative stress response, energy homeostasis, and apoptosis, though its precise physiological significance remains under investigation. FAHD1 dysregulation has been linked to metabolic disorders and neurodegenerative diseases, highlighting its biomedical relevance.
Recombinant FAHD1 is produced via heterologous expression systems (e.g., E. coli, mammalian cells) for structural and functional studies. Its recombinant form enables research into enzymatic mechanisms, substrate specificity, and interactions with metabolic pathways. Recent crystal structures have clarified active-site dynamics, aiding drug design targeting FAHD1-associated diseases. Challenges include optimizing protein solubility and stability due to its metal cofactor dependency. Current research focuses on elucidating FAHD1’s role in mitochondrial biology and its potential as a therapeutic target for metabolic or age-related pathologies.
×
